Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $109M | $118M | $120M | $128M | $133M | $148M | $152M | $149M | $143M | $137M |
| Revenue growth | — | 7.5% | 1.8% | 6.9% | 4.1% | 11.0% | 2.4% | -2.0% | -3.7% | -4.0% |
| Operating income | $31.2M | $34.2M | $35.3M | $43.0M | $42.7M | $50.3M | $46.5M | $40.0M | $35.2M | $22.6M |
| Operating margin | 28.5% | 29.1% | 29.5% | 33.6% | 32.0% | 34.0% | 30.7% | 27.0% | 24.6% | 16.4% |
| Net income | $20.5M | $22.9M | $30.0M | $32.4M | $37.3M | $37.5M | $31.8M | $31.0M | $24.8M | $11.6M |
| Net margin | 18.8% | 19.5% | 25.1% | 25.3% | 28.0% | 25.3% | 21.0% | 20.8% | 17.3% | 8.4% |
| EPS (diluted) | — | — | — | $1.26 | $1.45 | $1.46 | $1.27 | $1.25 | $1.04 | $50.00 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $26.8M | $28.1M | $39.8M | $40.9M | $40.6M | $46.3M | $36.3M | $38.1M | $34.6M | $26.4M |
| Capital expenditures | $3.97M | $4.57M | $5.97M | $4.66M | $3.98M | $5.51M | $9.84M | $15.8M | $15.4M | $10.7M |
| Free cash flow | $22.9M | $23.5M | $33.9M | $36.3M | $36.7M | $40.8M | $26.4M | $22.3M | $19.2M | $15.7M |
| Share buybacks | — | — | — | — | — | $4.14M | $27.6M | $19.1M | $30.9M | $20.2M |
| Dividends paid | $28.6M | $16.9M | $16.9M | $31.3M | $10.5M | $9.16M | $21.0M | $36.4M | $11.5M | $11.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $33.0M | $34.7M | $13.0M | $13.5M | $34.7M | $54.4M | $25.0M | $6.65M | $4.23M | $4.14M |
| Total assets | $121M | $127M | $108M | $111M | $133M | $158M | $130M | $122M | $133M | $135M |
| Total liabilities | $37.8M | $37.3M | $88.9M | $77.8M | $69.1M | $72.2M | $58.4M | $73.5M | $101M | $121M |
| Long-term debt | $857K | $1.07M | $34.2M | $29.8M | $26.5M | $26.6M | $22.3M | $29.5M | $57.9M | $75.0M |
| Shareholders' equity | $82.8M | $90.0M | $19.1M | $32.9M | $64.3M | $85.3M | $72.0M | $49.0M | $31.3M | $14.0M |
| Retained earnings | $71.5M | $77.6M | -$106M | -$93.4M | -$61.4M | -$36.1M | -$25.2M | -$30.5M | -$17.1M | -$17.3M |
| Shares (wtd avg diluted) | — | 20.9M | 24.8M | 25.7M | 25.7M | 25.6M | 25.1M | 24.7M | 23.7M | 22.4M |
Every figure is extracted from NRC HEALTH’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.